Pretreatment assessment of prognostic indicators in endometrial cancer

被引:53
作者
Mariani, A
Sebo, TJ
Katzmann, JA
Keeney, GL
Roche, PC
Lesnick, TG
Podratz, KC
机构
[1] Mayo Clin & Mayo Fdn, Dept Obstet & Gynecol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA
关键词
bcl-2; protein; curettage; cytokinetics; endometrial carcinoma; HER-2/neu oncogene; MIB-1 (Ki-67); p53 tumor suppressor gene; ploidy; prognosis; proliferating cell nuclear antigen;
D O I
10.1067/mob.2000.107328
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The object of this study was to assess the association of histologic, cytokinetic, and molecular variables in preoperative endometrial samples with extrauterine disease, recurrence, and survival among patients with endometrial cancer. STUDY DESIGN: In a case-cohort study of 125 women, ploidy, S-phase fraction, proliferative index. deoxyribonucleic acid index, proliferating cell nuclear antigen, MIB-1 proliferation marker, p53 tumor suppressor gene, and cytoplasmic HER-2/neu oncogene and bet-2 expressions were quantitated. RESULTS: A model with only one independent term predicted progression-free survival; that variable was p53 (P < .0001; relative risk, 5.60). A model with two independent terms predicted disease-related survival; these variables were p53 (P = .0002; relative risk, 7.39) and MIB-1 (P = .03; relative risk, 3.217). Among patients with tumors with both p53 and MIB-1 expression exceeding 33%, a total of 32% had died of disease by 2 years. A model for predicting extrauterine disease selected two independent variables: p53 (odds ratio, 3.20; P = .01) and ploidy (odds ratio, 2.16; P = .04). An advanced surgical stage was encountered in 26% to 35%:, of cases in which either the p53 expression exceeded 33% or the deoxyribonucleic acid content was nondiploid and in 53% of cases in which both variables were unfavorable. CONCLUSIONS: Preoperative evaluation of quantifiable cytokinetic and molecular variables can assist in identifying tumor types that are predisposed toward a more aggressive clinical course.
引用
收藏
页码:1535 / 1543
页数:9
相关论文
共 40 条
[1]  
Announcements, 1989, Gynecologic Oncology, V35, P125, DOI [DOI 10.1016/0090-8258(89)90027-9, 10.1016/0090-8258(89)90027-9]
[2]   ANALYSIS OF PCP-DATA TO DETERMINE FRACTION OF CELLS IN VARIOUS PHASES OF CELL-CYCLE [J].
BAISCH, H ;
GOHDE, W ;
LINDEN, WA .
RADIATION AND ENVIRONMENTAL BIOPHYSICS, 1975, 12 (01) :31-39
[3]   ROBUST VARIANCE-ESTIMATION FOR THE CASE-COHORT DESIGN [J].
BARLOW, WE .
BIOMETRICS, 1994, 50 (04) :1064-1072
[4]   DNA PLOIDY IN ENDOMETRIAL CARCINOMA - MAJOR OBJECTIVE PROGNOSTIC FACTOR [J].
BRITTON, LC ;
WILSON, TO ;
GAFFEY, TA ;
CHA, SS ;
WIEAND, HS ;
PODRATZ, KC .
MAYO CLINIC PROCEEDINGS, 1990, 65 (05) :643-650
[5]   Proliferating cell nuclear antigen in endometrial carcinoma: Pretreatment identification of high-risk patients [J].
Garzetti, GG ;
Ciavattini, A ;
Goteri, G ;
DeNictolis, M ;
Romanini, C .
GYNECOLOGIC ONCOLOGY, 1996, 61 (01) :16-21
[6]   Proliferation index determined by MIB-1 and recurrence in endometrial cancer [J].
Geisler, JP ;
Wiemann, MC ;
Zhou, Z ;
Miller, GA ;
Geisler, HE .
GYNECOLOGIC ONCOLOGY, 1996, 61 (03) :373-377
[7]   Lack of bcl-2 persistence: An independent prognostic indicator of poor prognosis in endometrial carcinoma [J].
Geisler, JP ;
Geisler, HE ;
Wiemann, MC ;
Zhou, Z ;
Miller, GA ;
Crabtree, W .
GYNECOLOGIC ONCOLOGY, 1998, 71 (02) :305-307
[8]   EFFECT OF SONICATION ON PARAFFIN-EMBEDDED TISSUE-PREPARATION FOR DNA FLOW-CYTOMETRY [J].
GONCHOROFF, NJ ;
RYAN, JJ ;
KIMLINGER, TK ;
WITZIG, TE ;
GREIPP, PR ;
MEYER, JS ;
KATZMANN, JA .
CYTOMETRY, 1990, 11 (05) :642-646
[9]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33
[10]   Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma [J].
Hamel, NW ;
Sebo, TJ ;
Wilson, TO ;
Keeney, GL ;
Roche, PC ;
Suman, VJ ;
Hu, TC ;
Podratz, KC .
GYNECOLOGIC ONCOLOGY, 1996, 62 (02) :192-198